Overview

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Status:
Completed

Trial end date:
2017-10-27

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and SOF/VEL FDC and ribavirin (RBV) for 12 weeks in participants with chronic genotype 3 hepatitis C virus (HCV) infection and compensated cirrhosis.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Ribavirin
Sofosbuvir
Sofosbuvir-velpatasvir drug combination
Velpatasvir